冠状动脉粥样硬化性心脏病经皮冠状动脉介入治疗(PCI)术后支架内再狭窄中西医研究现状  

After Percutaneous Coronary Intervention(PCI)for Coronary Atherosclerotic Heart Disease Research Status of Stent Restenosis in Chinese and Western Medicine

作　　者：赵阳[1] 焦晓民[2] ZHAO Yang;JIAO Xiaomin(Liaoning University of Traditional Chinese Medicine,Shenyang 110847,Liaoning,China;The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,Shenyang 110034,Liaoning,China)

机构地区：[1]辽宁中医药大学,辽宁沈阳110847 [2]辽宁中医药大学附属第二医院,辽宁沈阳110034

出　　处：《实用中医内科杂志》2022年第5期59-62,共4页Journal of Practical Traditional Chinese Internal Medicine

基　　金：辽宁省中医药临床重点学(专科)服务能力建设项目(LNZ-YXZK201907)。

摘　　要：近年来,我国疾病谱发生较大改变,临床工作中发现,人民越来越受到糖尿病病、高血压病、高脂血症及冠心病等慢性疾病的困扰,其中冠状动脉粥样硬化性心脏病占比较前明显增加。因此,结合中西医关于冠心病及冠心病支架植入术后支架内再狭窄的研究机制及治疗,有助于临床上对支架内再狭窄进行有效预防。In recent years,with the improvement of living standards,the development of science and technology and the advancement of medical standards,the spectrum of diseases in my country has undergone major changes.It has been found in clinical work that Chinese people are increasingly affected by diabetes,hypertension,hyperlipidemia and among chronic diseases such as coronary heart disease,the proportion of coronary heart disease has increased significantly.Therefore,the combination of traditional Chinese and western medicine on the research mechanism and treatment of coronary heart disease and in-stent restenosis after coronary heart disease stent implantation will help clinically effectively prevent in-stent restenosis.

关 键 词：冠状动脉粥样硬化性心脏病 经皮冠状动脉介入治疗 支架内再狭窄 

分 类 号：R541.4[医药卫生—心血管疾病]